title: TNF-alpha downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding.
abstract: Children with chronic inflammatory diseases experience growth failure and wasting. This may be due to growth hormone resistance caused by cytokine-induced suppression of growth hormone receptor (GHR) gene expression. However, the factors governing inflammatory regulation of GHR are not known. We have reported that Sp1 and Sp3 regulate hepatic GHR expression. We hypothesized that TNF-alpha suppresses GHR expression by inhibiting Sp1/Sp3 transactivators. LPS administration significantly reduced murine hepatic GHR expression, as well as Sp1 and Sp3 binding to GHR promoter cis elements. TNF-alpha was integral to this response, as LPS did not affect hepatic Sp1/Sp3 binding or GHR expression in TNF receptor 1-deficient mice. TNF-alpha treatment of BNL CL.2 mouse liver cells reduced Sp1 and Sp3 binding to a GHR promoter cis element and downregulated activity of a GHR promoter-driven luciferase reporter. Combined mutations within adjacent Sp elements eliminated GHR promoter suppression by TNF-alpha without affecting overall nuclear levels of Sp1 or Sp3 proteins. These studies demonstrate that murine GHR transcription is downregulated by LPS, primarily via TNF-alpha-dependent signaling. Evidence suggests that inhibition of Sp transactivator binding is involved. Further investigation of these mechanisms may identify novel strategies for preventing inflammatory suppression of growth.
authors.affiliation: Department of Pediatrics and Yale Child Health Research Center, Yale University School of Medicine, New Haven, Connecticut, USA. lee.denson@yale.edu
authors.forename: L A
authors.initials: LA
authors.lastname: Denson
authors.forename: R K
authors.initials: RK
authors.lastname: Menon
authors.forename: A
authors.initials: A
authors.lastname: Shaufl
authors.forename: H S
authors.initials: HS
authors.lastname: Bajwa
authors.forename: C R
authors.initials: CR
authors.lastname: Williams
authors.forename: S J
authors.initials: SJ
authors.lastname: Karpen
mesh_terms: D000818:Animals; D002648:Child; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation; D017930:Genes, Reporter / Q000235:genetics; D022781:Hepatocytes / Q000187:drug effects; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008099:Liver / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009687:Nuclear Proteins / Q000378:metabolism; D010957:Plasmids / Q000235:genetics / Q000378:metabolism; D011033:Podophyllin / Q000031:analogs & derivatives*; D011034:Podophyllotoxin / Q000031:analogs & derivatives; D011401:Promoter Regions, Genetic / Q000235:genetics; D011986:Receptors, Somatotropin / Q000235:genetics / Q000378:metabolism*; D016329:Sp1 Transcription Factor / Q000235:genetics / Q000378:metabolism*; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D004268:DNA-Binding Proteins; D008070:Lipopolysaccharides; D009687:Nuclear Proteins; D011986:Receptors, Somatotropin; D016329:Sp1 Transcription Factor; D015534:Trans-Activators; D014409:Tumor Necrosis Factor-alpha; C003170:mitopodozide; D011033:Podophyllin; D011034:Podophyllotoxin